AI-driven drug discovery company Lunai Bioworks Inc (NASDAQ: LNAI) reported on Wednesday that it has entered into a non-binding Letter of Intent through its BioSymetrics subsidiary with precision medicine data infrastructure company Geneial Inc to establish a strategic collaboration focused on rare neurological disorders and the creation of trial-ready patient cohorts to support pharmaceutical partnerships.

This initiative aims to convert fragmented patient-generated and registry data into structured, actionable datasets to accelerate drug development, improve clinical trial design and enable targeted engagement with pharmaceutical and biotechnology partners. Rare diseases affect approximately 300 million people globally, with rare neurological conditions representing a multi-billion-dollar market opportunity.

Under the proposed collaboration, Lunai Bioworks and Geneial plan to integrate and standardise patient-led datasets, identify defined patient subgroups, and generate insights to support therapeutic development. The programme is intended to facilitate the activation of trial-ready cohorts to streamline clinical research and reduce development risk.

The companies also expect to pursue downstream commercial opportunities with pharmaceutical partners, with the collaboration designed to support revenue-generating partnerships linked to cohort development and translational research.

Initial programmes will focus on select rare neurodevelopmental disorders, with scope for future expansion as part of a scalable data-driven rare disease research framework.